Optimizing Dosing of Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer: A Reminder That More Is Not Always Better
- 1 November 2023
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (31) , 4849-4851
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast CancerNew England Journal of Medicine, 2020
- Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 ActivityCancer Cell, 2019
- Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)Journal of Thoracic Oncology, 2019
- The Latest Research and Development into the Antibody–Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer TherapyChemical and Pharmaceutical Bulletin, 2019
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket TrialJournal of Clinical Oncology, 2018
- HER kinase inhibition in patients with HER2- and HER3-mutant cancersNature, 2018
- Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation studyThe Lancet Oncology, 2017
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Clinical Cancer Research, 2016
- Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumorsAnnals of Oncology, 2015
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung AdenocarcinomasClinical Cancer Research, 2012